EuroMAbNet: European Monoclonal Antibodies Network

Members

Armand Bensussan

Name of the laboratory

Members of the laboratory

Head of the Unit

Armand Bensussan armand.bensussan@inserm.fr

Researchers

Martine Bagot martine.bagot@aphp.fr

Anne Marie-Cardine anne.marie-cardine@inserm.fr

Laurence Michel laurence.michel@inserm.fr

Reem Al Daccak reem.al-daccak@inserm.fr

Gérard Chaouat gerard_chaouat@wanadoo.fr

Céleste Lebbé celeste.lebbe@aphp.fr

Nicolas Dumaz nicolas.dumaz@inserm.fr

Nicole Basset-Seguin nicole.basset-seguin@aphp.fr

Vincent Descamps vincent.descamps@aphp.fr

Sébastien Jauliac sebastien.jauliac@inserm.fr

Isabelle Petit isabelle.petit@inserm.fr

Daniel Aberdam daniel.aberdam@inserm.fr

Samia Mourah samia.mourah@aphp.fr

Caroline Ram-Wolff caroline.ram-wolff@aphp.fr

Ph.D. Students

Anne Caudron anne.caudron@inserm.fr

Florence Laugier florence.laugier@inserm.fr

Adèle De Masson adele.demasson@aphp.fr

Charlotte Hurabielle charlotte.hurabielle@gmail.com

Lauriane Roux lauriane.roux@inserm.fr

Technicians

Nicolas Thonnart nicolas.thonnart@inserm.fr

Valérie Dessirier valerie.dessirier@inserm.fr

Jocelyne André jocelyne.andre@inserm.fr

Edith Aberdam edith.aberdam@inserm.fr

Gabrielle Larcheron gabrielle.larcheron@inserm.fr

Frédéric Guaddachi frederic.gaddachi@inserm.fr

Valérie Schiavon valerie.schiavon@inserm.fr

Laboratory activity

Our laboratory is located at Saint Louis Hospital in Paris. We are working on the identification of new targets for the diagnosis and the therapy of skin diseases. Monoclonal antibodies are essential tools for determining the identification of these molecules. Dr. Armand Bensussan is the president of the French Association of Immunology, he is a member of the International HCDM (Human Cell Differentiation Molecules) Council.

Research activities

1. Physiopathology of Cutaneous T cell Lymphoma & Receptors of Innate Immunity

2. Oncogenesis of Melanoma

3. Epithelial pathophysiology, stem cells & tissue repair

Techniques available

• Monoclonal antibody production in mice
• Antibodies characterization
• Multi-colour flow cytometry
• Immunization with transfected cells

Publications (2018-present)

• Bensussan A, Marie-Cardine A. (2018) CD160. In Encyclopedia of Signaling Molecules. Ed : S. Choi, Springer. Second Edition, p. 846-852.
• Hurabielle C, Leboeuf C, Ram-Wolff C, Meignin V, Rivet J, Vignon-Pennamen MD, Bonnafous C, Sicard H, Fite C, Raffoux E, Arnulf B, Oksenhendler E, de Fontbrune FS, de Latour RP, Socié G, Bouaziz JD, Lebbé C, Bensussan A, Janin A, Bagot M, Battistella M. KIR3DL2 expression in patients with adult T-cell lymphoma/leukemia. Br J Dermatol. 2018 Jan 8. doi: 10.1111/bjd.16322.

Patents (2013-present)

• 2016 Invariant FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
• 2016 Ex vivo generation of γδ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
• 2016 Ex vivo generation of MHC II restricted CD4+ FoxP3+ regulatory T cells and therapeutic uses thereof, US patent, 5 august 2016
• 2016 Immunotherapeutic uses of ex vivo generated FoxP3+ regulatory T cells, US patent, 5 august 2016
• 2016 Monoclonal antibodies binding to the CD160 transmembrane isoform. EP 16306392.8, 25 october 2016
• 2016 Combinations therapies for treatment of cancer. EP 16305540, 10 may 2016. Licensed to OREGA Biotech
• 2015 Antibodies having specificity to myosin 18A and uses thereof. EP 15306108, 7 july 2015
• 2015 Methods and pharmaceutical compositions for the treatment of BRAF inhibitor resistant melanomas. EP 15306865, 25 november 2015
• 2013 KIR3DL2 is a biomarker and therapeutic target useful for respectively preventing and treating a subset of peripheral T-cell lymphomas. PCT/EP2013/061107, 29 may 2013
• 2013 IL-17 antagonist antibodies. EP 13731758.2, 25 june, 2013 Licensed to OREGA Biotech

Biotechnology company

• 2010/- OREGA-Biotech, 69000 Ecully, France
• 2017/- Alderaan Biotechnology, 75005 Paris